Shafique Virani
Directeur/Membre du Conseil chez TAUC3 Biologics Ltd.
Fortune : 1 M $ au 30/04/2024
Profil
Shafique Virani is currently a Director at TauC3 Biologics Ltd.
He previously served as the Chief Executive Officer at Navire Pharma, Inc., CoA Therapeutics, Inc., and Biobridge LLC.
Prior to that, he was the Vice President & Global Head-Neuroscience at Genentech, Inc. He holds a doctorate degree from The University of Nottingham.
He is currently serving as the Chief Medical & Business Officer at Recursion Pharmaceuticals, Inc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/04/2024 | 143 196 ( 0,07% ) | 1 M $ | 30/04/2024 |
Postes actifs de Shafique Virani
| Sociétés | Poste | Début |
|---|---|---|
TAUC3 Biologics Ltd.
 TAUC3 Biologics Ltd. BiotechnologyHealth Technology TAUC3 Biologics Ltd. is engaged in the biotechnology industry. The company was founded on July19, 2019 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | - |
Anciens postes connus de Shafique Virani
| Sociétés | Poste | Fin |
|---|---|---|
| RECURSION PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/06/2023 |
Navire Pharma, Inc.
 Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Navire Pharma, Inc. engages in the development of therapeutics to treat multiple cancers. It focuses on SHP2, a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signalling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. The company was founded by Phil Jones and Benjamin Neel in 2017 and is headquartered in San Francisco, CA. | Directeur Général | 01/12/2019 |
CoA Therapeutics, Inc.
 CoA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., CoA Therapeutics, Inc. is a biotechnology company based in San Francisco, CA. The company is targeting coenzyme-A (CoA) for patients with PKAN, organic acidurias, and other diseases of CoA sequestration. CoA plays a crucial role in energy metabolism and is implicated in a large number of disorders, from ultra-rare diseases like pantothenate kinase-associated neurodegeneration (PKAN) and organic acidurias (OAs), to common diseases such as type 2 diabetes. CoA Therapeutics is developing a novel small-molecule approach to modulate CoA levels by leveraging recent research about the CoA synthetic pathway. The company's approach and lead compounds are based on breakthrough scientific developments led by Suzanne Jackowski, Charles Rock, Richard Lee, and Stephen White at St. Jude Children's Research Hospital. | Directeur Général | 01/12/2019 |
| Biobridge LLC | Corporate Officer/Principal | 01/12/2019 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/06/2017 |
Formation de Shafique Virani
| The University of Nottingham | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| RECURSION PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Navire Pharma, Inc.
Navire Pharma, Inc. Pharmaceuticals: MajorHealth Technology Navire Pharma, Inc. engages in the development of therapeutics to treat multiple cancers. It focuses on SHP2, a protein-tyrosine phosphatase that links growth factor, cytokine and integrin signalling with the downstream RAS/ERK MAPK pathway to regulate cellular proliferation and survival. The company was founded by Phil Jones and Benjamin Neel in 2017 and is headquartered in San Francisco, CA. | Health Technology |
CoA Therapeutics, Inc.
CoA Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., CoA Therapeutics, Inc. is a biotechnology company based in San Francisco, CA. The company is targeting coenzyme-A (CoA) for patients with PKAN, organic acidurias, and other diseases of CoA sequestration. CoA plays a crucial role in energy metabolism and is implicated in a large number of disorders, from ultra-rare diseases like pantothenate kinase-associated neurodegeneration (PKAN) and organic acidurias (OAs), to common diseases such as type 2 diabetes. CoA Therapeutics is developing a novel small-molecule approach to modulate CoA levels by leveraging recent research about the CoA synthetic pathway. The company's approach and lead compounds are based on breakthrough scientific developments led by Suzanne Jackowski, Charles Rock, Richard Lee, and Stephen White at St. Jude Children's Research Hospital. | Health Technology |
TAUC3 Biologics Ltd.
TAUC3 Biologics Ltd. BiotechnologyHealth Technology TAUC3 Biologics Ltd. is engaged in the biotechnology industry. The company was founded on July19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
| Biobridge LLC |